1. , , , et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6: 734–46.
2. , , , et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 257–62.
3. , , , et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7: 280–92.
4. , , , et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7: 270–9.
5. , , , et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7: 263–9.
6. , , , et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984; 34: 939–44.
7. , , , Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010; 6: 131–44.
8. , , , et al. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 2011; 10: 230–40.
9. The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia. Acta Neuropathol 2010; 120: 131–43.
10. , , , , Quantification of alpha-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. Biomark Med 2010; 4: 683–99.
11. , , , et al. Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy. Brain 2010; 133: 2382–93.
12. , , , et al. New insights into biological markers of frontotemporal lobar degeneration spectrum. Curr Med Chem 2010; 17: 1002–9.
13. , , [Analysis of cerebrospinal fluid proteins in the diagnosis of Parkinson’s disease, Parkinson dementia and dementia with Lewy bodies.] Akt Neurol 2011; 38: 203–10.
14. , , , Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson’s disease. Acta Neuropathol 2010; 119: 703–13.
15. , , , et al. Salivary α-synuclein and DJ-1: potential biomarkers for Parkinson’s disease. Brain 2011; 134: e178.
16. , , , et al. Low incidence of post-lumbar puncture headache in 1,089 consecutive memory clinic patients. Eur Neurol 2010; 63: 326–30.
17. Dynamics of brain-derived proteins in cerebrospinal fluid. Clin Chim Acta 2001; 310: 173–86.
18. , , , The amyloid deposits in Alzheimer’s disease: their nature and pathogenesis. Appl Pathol 1984; 2: 357–69.
19. , , High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain. Neuroscience 2006; 143: 461–75.
20. , , , Amyloid beta-peptide and its relationship with dementia in Lewy body disease. J Neural Transm Suppl 1997; 51: 137–44.
21. , , Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies. Neurology 2000; 54: 1875–6.
22. , , , et al. Beta-amyloid 1–42 and tau-protein in cerebrospinal fluid of patients with Parkinson’s disease dementia. Dement Geriatr Cogn Disord 2006; 22: 200–8.
23. , , , Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson’s disease and progressive supranuclear palsy. Mov Disord 2003; 18: 186–90.
24. , , , et al. CSF amyloid β 1–42 predicts cognitive decline in Parkinson disease. Neurology 2010; 75: 1055–61.
25. , , , et al. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson’s disease: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry 2010; 81: 1080–6.
26. , , , et al. Decreased [beta]-amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration. J Neurol Sci 2005; 237: 61–5.
27. , , , et al. Tauopathies and synucleinopathies: do cerebrospinal fluid beta-amyloid peptides reflect disease-specific pathogenesis?J Neural Transm 2007; 114: 919–27.
28. , , , et al. Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias. Mol Psychiatry 2007; 12: 671–80.
29. , , , et al. CSF amyloid-β peptides in neuropathologically diagnosed dementia with Lewy bodies and Alzheimer’s disease. J Alzheimers Dis 2011; 24: 383–91.
30. , , Conservation of microtubule associated proteins. Isolation and characterization of tau and the high molecular weight microtubule associated protein from chicken brain and from mouse fibroblasts and comparison to the corresponding mammalian brain proteins. J Biol Chem 1979; 254: 12670–8.
31. , , , Occurrence of neuropil threads in the senile human brain and in Alzheimer’s disease: a third location of paired helical filaments outside of neurofibrillary tangles and neuritic plaques. Neurosci Lett 1986; 65: 351–5.
32. , , , et al. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem 1986; 261: 6084–9.
33. , , Neurodegenerative tauopathies. Annu Rev Neurosci 2001; 24: 1121–59.
34. , , , , Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 2000; 33: 95–130.
35. , Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration. Biochem J 1997; 323: 577–91.
36. , , , et al. Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample. Neurology 1999; 53: 1488–94.
37. , , , et al. Improved discrimination of AD patients using beta-amyloid(1–42) and tau levels in CSF. Neurology 1999; 52: 1555–62.
38. , , , et al. Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. Dement Geriatr Cogn Disord 2005; 19: 164–70.
39. , , , et al. The diagnostic value of cerebrospinal fluid tau protein in dementing and nondementing neuropsychiatric disorders. J Geriatr Psychiatry Neurol 2005; 18: 163–73.
40. , , , et al. A comparison of tau protein in cerebrospinal fluid between corticobasal degeneration and progressive supranuclear palsy. Neurosci Lett 1999; 259: 127–9.
41. , , , et al. Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer’s disease. Ann Neurol 2001; 50: 150–6.
42. , , , et al. Tau protein and 14–3–3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 2002; 58: 192–7.
43. , , , et al. Diagnostic problems during late course in Creutzfeldt-Jakob disease. J Neurol 2003; 250: 629–30.
44. , , , et al. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett 2001; 297: 187–90.
45. , , , et al. Neurochemical aftermath of amateur boxing. Arch Neurol 2006; 63: 1277–80.
46. , , , et al. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?Mol Chem Neuropathol 1995; 26: 231–45.
47. , , , et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996; 47: 1113–24.
48. , , , et al. Diagnostic significance of tau protein in cerebrospinal fluid from patients with corticobasal degeneration or progressive supranuclear palsy. J Neurol Sci 2001; 183: 95–8.
49. , , , et al. Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology. Biochem Biophys Res Commun 1997; 236: 262–4.
50. , , Advances in the development of biomarkers for Alzheimer’s disease: from CSF total tau and Abeta(1–42) proteins to phosphorylated tau protein. Brain Res Bull 2003; 61: 243–53.
51. , , , et al. Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol 2002; 59: 1267–72.
52. , , , et al. Elevated levels of phosphorylated neurofilament proteins in cerebrospinal fluid of Alzheimer disease patients. Neurosci Lett 2002; 320: 156–60.
53. , , , et al. Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology 2003; 60: 1586–90.
54. , , , et al. Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-epitopes in Lewy bodies in sporadic Parkinson’s disease and in dementia with Lewy bodies. Brain Res 1999; 843: 53–61.
55. , , , et al. Cerebrospinal fluid biomarkers in Parkinson’s disease with dementia and dementia with Lewy bodies. Biol Psychiatry 2008; 64: 850–5.
56. , , , et al. Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease. Mov Disord 2009; 24: 2203–10.
57. , , , et al. CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord 2010; 25: 2682–5.
58. , , , et al. Alpha-synuclein in Lewy bodies. Nature 1997; 388: 839–40.
59. , , , Multiple-system atrophy: a new alpha-synuclein disease?Lancet 1998; 352: 547–8.
60. , , , et al. Identification of novel alpha-synuclein isoforms in human brain tissue by using an online nanoLC-ESI-FTICR-MS method. Neurochem Res 2011; 36: 2029–42.
61. , , , et al. Alpha-synuclein implicated in Parkinson’s disease is present in extracellular biological fluids, including human plasma. Faseb J 2003; 17: 1945–7.
62. , , , et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A 2009; 106: 13010–5.
63. , , Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J Neurosci 2005; 25: 6016–24.
64. , , , et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 2011; 69: 570–80.
65. , , , , CSF α-synuclein does not differentiate between parkinsonian disorders. Neurobiol Aging 2012; 33: 430.e1–3.
66. , , , et al. Alpha-synuclein and chaperones in dementia with Lewy bodies. J Neuropathol Exp Neurol 2005; 64: 1058–66.
67. , , , et al. Low alpha-synuclein 126 mRNA levels in dementia with Lewy bodies and Alzheimer disease. Neuroreport 2006; 17: 1327–30.
68. , , , et al. Phosphorylation of Ser 129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem 2006; 281: 29739–52.
69. , Choroid plexus: target for polypeptides and site of their synthesis. Microsc Res Tech 2001; 52: 65–82.
70. , , , et al. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease. Biochem Biophys Res Commun 2006; 349: 162–6.
71. , , , et al. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson’s disease. Faseb J 2006; 20: 419–25.
72. , , , et al. Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 2010; 75: 1766–72.
73. , , Linking DJ-1 to neurodegeneration offers novel insights for understanding the pathogenesis of Parkinson’s disease. J Mol Med 2004; 82: 163–74.
74. , , , et al. Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases. J Biol Chem 2006; 281: 10816–24.
75. , , , et al. Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson’s disease. Biochem Biophys Res Commun 2006; 345: 967–72.
76. , , , et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease. Brain 2010; 133: 713–26.
77. , , , Biomarker-based dissection of neurodegenerative diseases. Prog Neurobiol 2011; 95: 520–34.
78. , Assembly of type IV neuronal intermediate filaments in nonneuronal cells in the absence of preexisting cytoplasmic intermediate filaments. J Cell Biol 1993; 122: 1323–35.
79. , , , et al. A new variant of Charcot-Marie-Tooth disease type 2 is probably the result of a mutation in the neurofilament-light gene. Am J Hum Genet 2000; 67: 37–46.
80. , , , et al. CSF biomarkers in the evaluation of idiopathic normal pressure hydrocephalus. Acta Neurol Scand 2007; 116: 333–9.
81. , , , et al. Neurofilament protein in cerebrospinal fluid: a marker of white matter changes. J Neurosci Res 2001; 66: 510–16.
82. , , , et al. Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD. Neurology 2000; 54: 1960–4.
83. , , , , Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: impact of SOD1 genotype. Eur J Neurol 2007; 14: 1329–33.
84. , , , et al. Subcortical vascular dementia biomarker pattern in mild cognitive impairment. Dement Geriatr Cogn Disord 2009; 28: 348–56.
85. , , Elevated neurofilament levels in neurological diseases. Brain Res 2003; 987: 25–31.
86. , , , , , The neurofilament heavy chain (NfH) in the cerebrospinal fluid diagnosis of Alzheimer’s disease. Dement Geriatr Cogn Disord 2006; 21: 291–5.
87. , , , , CSF-neurofilament and levodopa tests combined with discriminant analysis may contribute to the differential diagnosis of Parkinsonian syndromes. Parkinsonism Relat Disord 2001; 8: 23–31.
88. , , , Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson’s disease. Mov Disord 1998; 13: 70–7.
89. , , , , CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson’s disease. Neurobiol Aging 2007; 28: 742–7.
90. , , , et al. Neurofilament heavy-chain NfH(SMI35) in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes. Mov Disord 2006; 21: 2224–7.
91. , Tissue-specific functions in the fatty acid-binding protein family. J Biol Chem 2010; 285: 32679–83.
92. , , , , Human heart-type fatty acid-binding protein as an early diagnostic and prognostic marker in acute coronary syndrome. Cardiology 2003; 99: 96–104.
93. , , , et al. Fatty acid-binding protein and the early detection of acute myocardial infarction. Clin Chim Acta 1998; 272: 87–92.
94. , , , Analysis of the tissue-specific expression, developmental regulation, and linkage relationships of a rodent gene encoding heart fatty acid binding protein. J Biol Chem 1987; 262: 9709–17.
95. , , , , Brain arachidonic acid incorporation is decreased in heart fatty acid binding protein gene-ablated mice. Biochemistry 2005; 44: 6350–60.
96. , , , Heart type fatty acid binding protein (H-FABP) is decreased in brains of patients with Down syndrome and Alzheimer’s disease. J Neural Transm Suppl 2003; 67: 225–34.
97. , , , et al. CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer’s disease. J Alzheimers Dis 2010; 22: 1281–8.
98. , , , et al. Heart fatty acid binding protein as a potential diagnostic marker for neurodegenerative diseases. Neurosci Lett 2004; 370: 36–9.
99. , , , et al. Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies. Neurodegener Dis 2007; 4: 366–75.
100. , , Purification and some characteristics of an ACTH-sensitive protein kinase and its substrate protein in rat brain membranes. J Neurochem 1980; 34: 1689–99.
101. , , , Cloning of complementary DNA for GAP-43, a neuronal growth-related protein. Science 1987; 236: 597–600.
102. , , Phosphorylation of B-50 protein by calcium-activated, phospholipid-dependent protein kinase and B-50 protein kinase. J Neurochem 1983; 41: 649–53.
103. , , Growth-associated protein, GAP-43, a polypeptide that is induced when neurons extend axons, is a component of growth cones and corresponds to pp46, a major polypeptide of a subcellular fraction enriched in growth cones. Proc Natl Acad Sci U S A 1986; 83: 3537–41.
104. , , , Immunohistochemical localization of a phosphoprotein (B-50) isolated from rat brain synaptosomal plasma membranes. Brain Res Bull 1981; 6: 145–53.
105. , , , et al. CSF levels of tau, beta-amyloid(1–42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J Neural Transm 2000; 107: 563–79.
106. , , , et al. The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer’s disease, reflecting a common pathophysiological process. Dement Geriatr Cogn Disord 2001; 12: 257–64.